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Artificial Organs: SynCardia Heart 
Kaity Keesling 
Abstract: With an increased prevalence of cardiovascular disease, heart transplants are on the rise. As a result, the need for donor hearts 
exceeds current availability. To care for heart failure patients, healthcare professionals have developed the SynCardia total artificial heart. 
This article explains the artificial heart and its implementation into clinical practice. 
pressing public health issue currently affecting the United
States is the rising prevalence of heart disease. This illness
accounted for over 600,000 deaths in 2016, placing heart 
disease as the leading cause of death in the nation.1 While the 
demand for heart transplants grows in response to increasing 
disease prevalence, the availability of donor organs remains 
unchanged. This disparity between supply and demand has led 
medical professionals to seek solutions elsewhere. An alternative 
for patients in need of a new organ is the utilization of artificial 
organs. An artificial organ is any human made machine, device, 
tissue or other material that is used to replace the functions of an 
organ in the human body.2 In order to combat the high mortality 
rates related to heart disease, the total artificial heart (TAH) was 
developed. This device is a pump that is surgically inserted to 
replace diseased or damaged heart ventricles and provide 
circulation.3 Although the artificial heart is not a permanent 
solution, it buys patients time until they receive a heart transplant. 
The growing prevalence of heart disease has created an imbalance 
between availability and need of donor organs. However, the 
artificial heart serves as a lifesaving solution for patients awaiting 
a transplant.  
As heart disease continues to rise and cause health complications, 
the number of people waiting for a new heart has increased as well. 
To date, there are over 3,700 people on the heart transplant 
waiting list, which drastically exceeds organ availability.4 For those 
in need of a transplant, the waiting time is often long because the 
donor heart must be similar in size and blood type. This long 
waiting period can be extremely difficult to endure, especially for 
those in end stage heart failure. The low donor availability 
combined with unfavorable heart health conditions continues to 
split the gap between organ supply and demand, encouraging 
medical professionals to seek alternative care options.  
Artificial organs were developed to meet the high demand for 
organ transplants. Artificial organs vary greatly, depending on the 
structure and function they are intended to replace. While many 
artificial organs are completely synthetic, others are grown in a lab. 
Lab grown organs use stem cells to regenerate, repair, or replace 
damaged tissue or whole organs.5 Potential advantages of lab 
grown organs include reduced likelihood of transplant rejection 
and permanent replacement of the faulty organ or tissue. Still, 
complex organs such as the heart are difficult to produce in this 
manner.5 Due to its size and complexity, stem cells are unable to 
generate a fully functioning, adult-sized heart. Instead, artificial 
hearts are made from biocompatible plastic. This type of plastic 
minimizes the likelihood of rejection so that the body is more likely 
to accept the artificial organ.  
The first recorded artificial heart transplant performed on a 
human occurred in 1982 using the Jarvik-7 model heart.6  Today, 
the Total Artificial Heart (TAH) by SyCardia is the only FDA 
approved fully synthetic heart that is designed for use as a 
temporary bridge to live organ transplant.7  It is a pump that is 
surgically installed to provide circulation and replace heart 
ventricles that are diseased or damaged. The structure of the 
synthetic heart closely mimics that of a natural, live heart.8 The 
TAH contains two artificial ventricles made from biocompatible 
plastic. The two ventricles are connected in the middle by velcro, 
which allows unique positioning and placement of the heart 
depending on the anatomy of each individual patient. An 
external machine performs the pumping action rather than live 
muscle tissue.8   
Within each ventricle in the artificial heart are two valves, one for 
inflow and one for outflow, which control the movement of 
blood in and out of the heart.8  There is also a flexible diaphragm 
membrane which splits each ventricle into two chambers, one for 
air and one for blood. The formation of these two areas helps the 
external pumping system control blood flow by inflating and 
deflating portions of the heart in a regular pattern. The tubes that 
connect the internal artificial heart to the external system that 
regulates blood flow are called cannulae. These tubes are 
partially covered in velour fabric, similar to a plush velvet, 
promoting proper healing at the tube exit site through the 
abdominal wall. The cannulae connect further to two additional 
external tubes called drivelines which connect to the external 
pumping system.8  
Along with the artificial heart on the interior of the body, external 
drivers, which act as the battery pumping the heart, are equally 
necessary. There are various types of external drivers that serve 
different purposes, depending on the situation and needs of the 
patient. Some external pumping systems are portable while 
others are not, but each work in a similar way. The machine 
produces pulses of air and vacuum in order to inflate and deflate 
the diaphragms which push blood in and out of the ventricles.8 
In 2004, the CCS driver was approved for medical use, followed 
by the C2 driver in 2012. Although effective and serve their 
intended purpose, these batteries limit patient freedom since 
they are used in a stationary position, typically in a hospital.7 A 
new model called the Freedom Driver was FDA approved in 2014, 
granting freedom of movement to patients who received a total 
artificial heart.7 Patients can be switched to this lighter, portable 
battery and sent home once they are clinically stable. The  
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minimal maintenance and ease of use allow patients to lead a 
nearly normal lifestyle while waiting for a donor heart.  
 
Since its approval, the SynCardia heart has been implanted over 
1300 times in the United States, Canada, and Europe.9 As a result, 
total artificial heart transplants have dramatically improved the 
‘bridge to transplant’ survival period from 46% to >79%.10 The 
limitations to its efficacy include durability and length of time the 
artificial heart can remain in a person’s body without causing 
secondary complications. The longest known usage of the 
SynCardia total artificial heart is currently 4.6 years or 
approximately 1700 days.11 Since it’s not a permanent solution to 
poor heart health, an artificial heart is only indicated to sustain life.  
Criteria to meet eligibility requirements for a TAH are very 
specific.12 First, a patient must be suffering from very advanced or 
end stage heart failure. Both sides of the heart (biventricular) must 
also be affected. Lastly, patients must be eligible or likely to 
become eligible for a heart transplant. Since heart failure is 
irreversible, the TAH is the greatest chance for survival until a 
donor heart becomes available.12 However, it comes at a high cost. 
The estimated cost of a TAH is about $150,000 without insurance, 
though this cost may differ depending on who performs the 
transplant.10 Despite this high price tag, most insurance companies 
will cover the majority of expenses. There is little to no cost for 
upkeep of the synthetic heart, although there is some maintenance 
work to ensure its continued efficacy. 
 
In response to the growing prevalence and mortality related to 
heart disease, the United States has a growing disparity between 
the need and supply of donor organs available for transplant. The 
excess demand for life-saving intervention has led to the 
development of a wide variety of artificial organs. While many of 
these devices are not intended for permanent use, like the 
SynCardia total artificial heart, they are effective at bridging 
patients to transplant of a live organ. The future of artificial organs 
is promising, as more effective treatment options are being 
developed, allowing for increased quality of patient care as 
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